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Abstract
Background: The possible emergence of resistance to the only available drug for schistosomiasis spurs drug discovery that
has been recently incentivized by the availability of improved transcriptome and genome sequence information. Transient
RNAi has emerged as a straightforward and important technique to interrogate that information through decreased or loss
of gene function and identify potential drug targets. To date, RNAi studies in schistosome stages infecting humans have
focused on single (or up to 3) genes of interest. Therefore, in the context of standardizing larger RNAi screens, data are
limited on the extent of possible off-targeting effects, gene-to-gene variability in RNAi efficiency and the operational
capabilities and limits of RNAi.
Methodology/Principal Findings: We investigated in vitro the sensitivity and selectivity of RNAi using double-stranded
(ds)RNA (approximately 500 bp) designed to target 11 Schistosoma mansoni genes that are expressed in different tissues;
the gut, tegument and otherwise. Among the genes investigated were 5 that had been previously predicted to be essential
for parasite survival. We employed mechanically transformed schistosomula that are relevant to parasitism in humans,
amenable to screen automation and easier to obtain in greater numbers than adult parasites. The operational parameters
investigated included defined culture media for optimal parasite maintenance, transfection strategy, time- and dose-
dependency of RNAi, and dosing limits. Of 7 defined culture media tested, Basch Medium 169 was optimal for parasite
maintenance. RNAi was best achieved by co-incubating parasites and dsRNA (standardized to 30 mg/ml for 6 days);
electroporation provided no added benefit. RNAi, including interference of more than one transcript, was selective to the
gene target(s) within the pools of transcripts representative of each tissue. Concentrations of dsRNA above 90 mg/ml were
directly toxic. RNAi efficiency was transcript-dependent (from 40 to .75% knockdown relative to controls) and this may
have contributed to the lack of obvious phenotypes observed, even after prolonged incubations of 3 weeks. Within minutes
of their mechanical preparation from cercariae, schistosomula accumulated fluorescent macromolecules in the gut
indicating that the gut is an important route through which RNAi is expedited in the developing parasite.
Conclusions: Transient RNAi operates gene-selectively in S. mansoni newly transformed schistosomula yet the sensitivity of
individual gene targets varies. These findings and the operational parameters defined will facilitate larger RNAi screens.
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Schistosomiasis is one of a number of ‘neglected tropical
diseases’ (NTDs) associated with extreme poverty in the world’s
‘bottom billion’ people [1]. Caused by a parasitic flatworm, the
disease can be fatal, but is better known for its chronicity of
infection (e.g., [2]). Clinical manifestations of chronic infection
include malaise, anemia and wasting, and poor cognitive
performance in children [3,4,5,6,7]. Infection with Schistosoma
haematobium is associated with an increased risk of bladder cancer
[8,9] and due to the compromised integrity of the lower female
genital tract, with HIV infection [1,9,10].
Because treatment and control of schistosomiasis has come to
rely on a single drug, praziquantel (PZQ; [11,12,13]), concern
remains over the possible emergence and establishment of
clinically relevant drug resistance [14]. There are reports of
decreased, if sometimes, transient [15], susceptibility by field-
isolates of parasite to PZQ [16]. The risk of resistance to PZQ
[14,17] is all the more relevant given the impetus to increase access
to this and other anthelmintics via integrated mass administration
programs [18,19,20,21,22]. Thus, it remains a priority to identify
and develop alternative chemo- and immuno-therapeutic inter-
ventions for schistosomiasis, and progress is being made in both
these areas [23,24,25,26,27].
Key initial tasks for drug development are the identification and
validation of gene products for which modulation by chemical
and/or genetic means translates to impaired cell/organism
survival. For schistosomes, comprehensive transcriptome
[28,29,30,31,32,33,34,35,36] and genome sequence information
[37,38,39] is now accessible through interrogable databases
[37,40,41,42]. These databases have facilitated new strategies,
e.g., [43,44,45], with which potential gene targets have been
identified, e.g., [46]. Coincident with these developments is the
continued focus to improve a number of reverse genetic tools to
define gene function [47,48,49,50]. Since the first reports in 2003
[51,52], transient RNA interference (RNAi) with either long or
short-interfering (si) double-stranded (ds)RNA has proven a
straightforward and important tool to study loss of or decreased
function for selected genes of interest, including proteases
[53,54,55,56],kinases [57], TGF-beta receptor [58], aquaporin
[59], glucose transporters [60], tetraspanins [61] and redox-
associated enzymes [62,63]. In some of these studies obvious
phenotypes that affected parasite vitality and/or survival were
obtained. This evidence for RNAi in schistosomes is underpinned
by in silico and experimental data to suggest that the necessary
RNAi molecular machinery is present [33,64,65,66]. Accordingly,
larger scale RNAi screening campaigns of schistosomes can be
now envisaged.
To date, RNAi studies with schistosomes relevant to infection in
humans have focused on single (or up to 3; [55,65]) genes of
interest using different developmental stages and experimental
conditions. Thus, the studies only partially contribute to
standardizing a set of conditions that are applicable to larger
scale investigations of gene function. Furthermore, the degree to
which complicating factors such as individual gene susceptibility to
RNAi and ‘off-targeting’ (whereby dsRNA can direct the RNAi
machinery to target transcripts other than that intended) occur is
unknown. The latter phenomenon can confound interpretations of
loss-of-function [67,68,69,70,71,72], especially when phenotypes
are generated [73]. Both issues were highlighted in a recent RNAi
phenotypic screen of 32 genes in the mother sporocyst stage of
Schistosoma mansoni that parasitizes the snail vector [74,75].
As a pre-requisite to larger RNAi-based screens of schistosome
stages infecting humans, we investigated the issues of target
selectivity and sensitivity of RNAi for 11 gene transcripts expressed
in different tissues of S. mansoni, including genes predicted in silico
as being essential to parasite survival [46]. We focused on
mechanically transformed schistosomula, which, compared to
adult schistosomes, are easier to procure in their hundreds of
thousands from snails and adaptable to automated higher
throughput screening technologies [76]. Schistosomula also offer
the opportunity to identify genes of potential value as chemo- or
immuno-therapeutic targets prior to the onset of disease pathology
and morbidity associated with egg-laying adults. At the same time,
we examined a number of operational parameters (optimal
medium for parasite maintenance, transfection strategy and
time-, and dose-dependencies of RNAi) for which refinement
would better facilitate larger-scale loss-of-function screens.
Materials and Methods
Ethics Statement
Maintenance of and experiments with vertebrate animals were
carried out in accordance with protocols approved by the
Institutional Animal Care and Use Committee (IACUC) at UCSF.
S. mansoni life-cycle and preparation of schistosomula
A Puerto Rican isolate of S. mansoni is maintained in the
laboratory using the intermediate snail host, Biomphalaria glabrata
and the Golden Syrian hamster, Mesocricetus auratus, (infected at 5–
6 weeks old; Simonsen) as the definitive host [76]. Methods for the
preparation of newly transformed schistosomula (hereafter termed
schistosomula) are described previously [76]. Essentially, the
procedure involves cleaning cercariae from snail water and
mechanically shearing cercarial tails from heads [77] (the nascent
schistosomula) in ice-chilled Basch Incomplete Medium 169 [78]
(custom synthesized at the UCSF Cell Culture Facility; containing
100 U/ml penicillin and 100 mg/ml streptomycin, but without
FBS). Schistosomula are collected and washed three times in the
same medium and kept on ice for a maximum of 1 h prior to
dsRNA treatment.
Author Summary
RNA interference (RNAi) is a technique to selectively
suppress mRNA of individual genes and, consequently,
their cognate proteins. RNAi using double-stranded (ds)
RNA has been used to interrogate the function of mainly
single genes in the flatworm, Schistosoma mansoni, one of
a number of schistosome species causing schistosomiasis.
In consideration of large-scale screens to identify candi-
date drug targets, we examined the selectivity and
sensitivity (the degree of suppression) of RNAi for 11
genes produced in different tissues of the parasite: the gut,
tegument (surface) and otherwise. We used the schisto-
somulum stage prepared from infective cercariae larvae
which are accessible in large numbers and adaptable to
automated screening platforms. We found that RNAi
suppresses transcripts selectively, however, the sensitivity
of suppression varies (40%–.75%). No obvious changes in
the parasite occurred post-RNAi, including after targeting
the mRNA of genes that had been computationally
predicted to be essential for survival. Additionally, we
defined operational parameters to facilitate large-scale
RNAi, including choice of culture medium, transfection
strategy to deliver dsRNA, dose- and time-dependency,
and dosing limits. Finally, using fluorescent probes, we
show that the developing gut allows rapid entrance of
dsRNA into the parasite to initiate RNAi.
RNAi in S. mansoni Schistosomula
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To compare the effects of different defined culture media on
parasite vitality, 200–300 schistosomula were incubated in 96-well
flat-bottom plates (Corning) containing 200 mL medium, 5% FBS
and 100 U/ml penicillin and 100 mg/ml streptomycin for up to 7
days at 5% CO2 and 37uC. Media tested were: Basch Medium
169; DMEM (high glucose; UCSF cell culture facility code
CCFAA005); F-12 (CCFAB002); Liebovitz’s L-15 Medium
without NaHCO3 (CCFDY003); M199 with Earle’s Salts
(CCFAX001); RPMI 1640 (containing 2mM glutamine
(CCFAE001) and supplemented with 10 mM HEPES), and
Schneider’s Drosophila Medium (INVZR512). Phenotypic alter-
ations in translucency, shape and motility [76] were assessed every
second day. Still and time-lapse image recordings were made on
the seventh day.
Transcript targets
We selected 11 genes encoding diverse proteins and putatively
expressed in different tissues (gut, tegument and otherwise) in order to
assess any variability in the ability to suppress gene transcription. For
gut genes, we chose 3 well-characterized S. mansoni proteases;
cathepsin B1 (using a dsRNA targeting both isoforms - CB1.1
(AJ506157) and CB1.2, (AJ506158), cathepsin C (CC, Z32531) and
cathepsin D (CD, U60995) [54,79]. For the tegument, 3 genes were
chosen; CB2 (AJ312106), annexin (XP_002578945.1) and Sm29
(XP_002578407.1). The respective proteins have been bio/immuno-
chemically localized to the parasite surface [80,81,82] although CB2 is
also localized in the parenchyma [82]. Annexin is also a protein
common to most eukaryote plasma membranes [83] and may,
therefore,be moregenerallydistributed in theparasite.Theremaining
5 targets are considered to be more generally distributed and have
been predicted to be essential in S. mansoni in a recent comparative
genomics analysis [46]: glycogen synthase kinase-3 (GSK3; XP_0025-
72305.1), methionine aminopeptidase (MetAP; XP_002572573.1),
protein phosphatase-2a (PP-2a; XP_002574514.1), neuroendocrine
convertase (NEC; XP_002569775.1) and n-myristoyl transferase
(nMT; XP_002571399.1). Table S1 describes the primers used for
dsRNA synthesis (the T7 DNA polymerase binding motif is shown in
bold characters) and the quantitative real-time (qRT)-PCR primers
used to measure RNAi. For dsRNA design, the nucleotide sequence
encoding the open reading frame of each gene target was examined
using the nucleotide BLAST service at NCBI (constrained to the
Schistosoma taxid ID of 6181). Sequence areas displaying homology
(especially for identical stretches of 10 nucleotides or more) with other
Schistosoma genes were avoided in order to decrease the risk of
off-targeting.
Synthesis of dsRNA and Cy5-labeled dsRNA
PCR products of approximately 500 bp in size were amplified
from cDNA prepared from 6 day-old in vitro cultivated S. mansoni
schistosomula cDNA using gene-specific primers for the targeted
genes (Table S1). The expected size of the amplicon was measured
by electrophoresis in 1% agarose gels and identity confirmed by
DNA sequencing. Amplicons were then used as templates for two
more PCR reactions using either a sense or antisense primer
containing a 59-positioned T7 polymerase promoter sequence.
After gel purification, each of the two PCR products was
separately reverse transcribed in vitro using the T7 RiboMAX
express RNAi system (Promega) and the resulting single-stranded
RNA pooled to generate dsRNA that was then treated with RNase
A and DNase. The manufacturer’s instructions were applied apart
from scaling the reverse transcription reaction to 100 ml and
allowing it to proceed overnight at 37uC with a final hour at 42uC.
The dsRNA was precipitated using 1 volume of 10% 3 M sodium
acetate (pH 5.2) in 100% isopropanol, and pelleted at 12 000 g for
15 min at 4uC. The pellet was washed in 70% ethanol, air-dried
and resuspended in water. The concentration of dsRNA was
measured in an ND-1000 Spectrophotometer (Nanodrop Tech-
nologies) and adjusted to 3.0 mg/ml. The size and integrity of the
resulting dsRNA was confirmed by electrophoresis in 1% agarose
gels and stored at 280uC until use.
For synthesis of Cy5-labeled dsRNA to CC, CB1 and the
Discosoma sp. fluorescent protein, mCherry ([84]; GenBank
AY678264), an aliquot of dsRNA (40 mg) was labeled using the
Label IT Nucleic Acid Labeling Reagent (Mirus) according to the
manufacturer’s instructions. Labeling efficiency was monitored
using an ND-1000 Spectrophotometer.
Treatment of schistosomula with dsRNA
Schistosomula were divided into groups of approximately 400
and incubated in 24-well plates containing 1 ml Complete
Medium 169 (plus 5% FBS) and dsRNA (30 mg unless otherwise
stated) targeting either schistosome transcripts or mCherry that
was employed as a schistosome-unspecific control. Incubations
were continued for 6 days at 37uC and 5% CO2. To isolate for the
effect of electroporation on RNAi efficiency, the following
additional incubations were set up. Groups of 400 schistosomula
were transferred to 4 mm electroporation cuvets (Bio-Rad
Laboratories) in Basch Incomplete Medium 169. DsRNA (30 mg)
was then added (usually as a 10 mL aliquot) in Incomplete Medium
169 to give a final volume of 100 ml. Electroporation was carried
at 125 V for 20 ms [53] using a Bio-Rad GenePulser Xcell.
Worms were then suspended in 1 ml Complete Medium 169 and
incubations continued for 6 days. A second group of worms was
electroporated as above, but following electroporation, worms
were washed 10 times in Incomplete Medium 169 to remove as
much dsRNA as possible and then incubated at 37uC. A third
group was electroporated in the absence of dsRNA, and
immediately thereafter dsRNA was added for incubation at 37uC.
RNA isolation from schistosomula after dsRNA treatment
and conversion to cDNA
After 6 days of cultivation, schistosomula were collected, washed
3 times in 1.5 ml PBS and resuspended in 50 ml of Trizol reagent
(Invitrogen). Samples were flash frozen in liquid nitrogen and
stored at 280uC. During thawing, samples were homogenized
with Kontes disposable pellet pestles and microtubes (VWR).
Sample volumes were adjusted to 500 ml with Trizol reagent and
the temperature adjusted to 65uC for 5 min to improve tissue lysis.
To separate nucleoprotein complexes, samples were further
incubated at room temperature for 15–20 minutes. Steps to
continue the isolation of total RNA with Trizol were performed up
until phase separation in chloroform. At this point, the aqueous
phase was transferred to a new 1.5 ml microfuge tube containing
an equal volume of 75% ethanol. RNA was further purified using
the RNeasy Mini Kit (Qiagen) according to the supplied
instructions. The concentration of RNA was determined using
an ND-1000 Spectrophotometer. Single-stranded cDNA was
synthesized from total RNA using SuperScript III reverse
transcriptase (Invitrogen) and an oligo d(T)18 reverse primer
according to the manufacturer’s protocol. The resulting cDNA
was purified using a DNA Clean & Concentrator-5 (Zymo
Research Corporation) and stored in water at 280uC.
Primer design and optimization, and qRT-PCR analyses
Primers were designed using the Primer 3 software (http://
frodo.wi.mit.edu/, [85]) employing a target product size of 150–
RNAi in S. mansoni Schistosomula
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excluded outputs containing stretches of four or more of identical
nucleotides that might interfere with binding specificity. Primers
were designed to bind outside of the region targeted by the dsRNA
to avoid the possibility of amplifying carryover PCR product used
as a template in dsRNA synthesis reaction. The specificity of each
primer sequence was confirmed by BLAST analysis. Primers were
purchased from Integrated DNA Technologies at the 25 nM scale
and without additional purification procedures. The size of PCR
amplicon generated by each primer pair was visually inspected by
1% agarose gel electrophoresis to ensure that the intended sized
product was in fact amplified. The amplification efficiency of each
qRT-PCR primer set was evaluated in triplicate over at least three
and five dilutions of primers and cDNA template, respectively.
The cycle threshold (CT) values arising were plotted as a function
of the dilution of cDNA [86]. Optimal efficiencies generated
curves with slopes of between 23.5 and 23.2 (100% efficiency is
represented by a gradient of 23.32). R
2 coefficients of $0.98
indicated high reproducibility for the triplicate reactions. Primer
sets were also checked for their dissociation (melting) curves using
the appropriate setting of the MxPro QPCR software package (see
below). Only those primers displaying optimal efficiencies and
generating single dissociation peaks (the latter demonstrative of a
specific reaction without, for example, primer dimerization) [87]
were considered further. Our experience has been that, for each
transcript target, two to four primer sets needed to be tested in
order to identify an optimal pair.
Quantitative RT-PCR was carried out in an MX 3005P Real-
Time PCR cycler (Stratagene, Agilent Technologies, Inc.) using
the LightCycler 480 SYBR Green I Master mix (Roche
Diagnostics). S. mansoni cytochrome C oxidase I (GenBank
AF216698, [88]) served as the sample normalizing gene transcript
[89]. This transcript is highly and constitutively expressed in a
number of S. mansoni life-cycle stages [30]. Controls for genomic
DNA contamination (minus reverse transcriptase) and reagent
purity (water control) were included for each sample. Reactions
were carried out in a final volume of 25 ml in 96 well plates
(Stratagene). The amplification profile consisted of an initial hot
start (95uC for 10 min), followed by 40 cycles comprising 95uC for
30 s, 55uC for 60 s and 72uC for 60 s, and ended with a single
cycle of 95uC for 60 s, 55uC for 30 s and 95uC for 30 s. PCR
reactions were performed in duplicate for each cDNA sample.
Also, at least one additional biological replicate, i.e., with cDNA
arising from a separate dsRNA application, was performed. To
ensure precision, the entire qPCR experiment was repeated when
CT values of duplicate reactions differed by 0.5 or more (indicative
of pipeting error). Using the MxPro QPCR Software version 4.01
(Stratagene), the 2
2DDC
T method [90] was applied to measure
transcript levels following dsRNA treatment. Transcript levels
were expressed as a percentage of those following exposure to
schistosome-unspecific mCherry dsRNA.
Irreversible active site labeling of SmCC
To verify RNAi of SmCC at the protein level, the fluorescent
and selective cathepsin C affinity probe bodipy-labeled FY01 [91]
was incubated with protein extract from schistosomula exposed to
SmCC-dsRNA. Extracts from worms incubated with mCherry-
dsRNA served as a control. Soluble protein extracts were prepared
by sonication in 50 mM citrate, 100 mM phosphate, pH 5.0 over
an ice bath. After centrifugation at 8 000 g and 4uC for 5 min,
supernatants were collected. An aliquot (2 mg protein) was
incubated for 1 h at 37uC with 1 mM bodipy-labeled FY01 in
50 mM sodium acetate pH 5.5 containing 2.5 mM DTT, 1 mM
EDTA and 1 mM each of the respective aspartic and cathepsin B
(cysteine protease) inhibitors, pepstatin A and CA-074 (N-[L-3-
trans-propylcarbamoyloxirane- 2-carbonyl]-Ile-Pro-OH [92]; Ba-
chem). The labeling reaction was stopped by heating to 70uC for
15 min in reducing Laemmli sample buffer. The reaction mixture
was resolved by SDS-PAGE through 15% polyacrylamide gels and
visualized in a Typhoon 8600 Imager (GE Healthcare) using
excitation at 532 nm (green laser) and a 580 nm (BP30 nm)
emission filter.
SmCC activity was also detected by hydrolysis of the cathepsin
C fluorogenic substrate, Gly-Arg-AMC, as described previously
[93], in the presence and absence of 10 mM of the following
protease inhibitors (Bachem): the general Clan CA cysteine
protease inhibitor, K11777 (N-methyl-piperazine-Phe-homoPhe-
vinyl sulfone phenyl [94]); the cathepsin B-selective inhibitor, CA-
074; and the cathepsin L-preferential inhibitor, Z-Phe-Phe-DMK
(benzyloxy carbonyl-Phe-Phe-diazomethane [95]). Assays were
performed in triplicate.
Preparation of recombinant mCherry fluorescent protein
The mushroom anemone (Discosoma sp.) red fluorescent protein,
mCherry [84], was recombinantly expressed in TOP10 chemically
competent E. coli (Invitrogen). Bacteria that had been transformed
with the mCherry open reading frame as part of a pUC18 plasmid
backbone were grown overnight at 37uC in 500 ml LB medium
containing 100 mg/ml of ampicillin and 20 mM glucose. After
centrifugation at 3 000 g for 10 min, bacteria were incubated for
4 h in fresh LB medium containing 1 mM IPTG (isopropyl-b-D-
thio-galactoside) and harvested by centrifugation for 10 min at
4 000 g. The pellet was re-suspended in 50 ml 100 mM phosphate
buffer, pH 8.0, and sonicated using a Branson Sonifier 250
adjusted to a 60% duty cycle and an output control of 6. The
material was centrifuged at 10 000 g for 15 min and the
supernatant, containing recombinant mCherry, was collected.
Heat denaturation in a water bath at 80uC for 40 min followed by
centrifugation at 10 000 g for 15 min was employed to separate
bacterial proteins from the heat-stable mCherry protein in the
supernatant. The supernatant was decanted and concentrated
over an Amicon Ultra-50 10K (Millipore) filter to a final volume of
5 ml. The sample was size fractionated over a Superdex 200
column (GE- Healthcare) pre-equilibrated with 100 mM phos-
phate buffer, pH 8.0. Eluted fractions containing visible red
mCherry protein (4 mg/ml) were pooled and stored at 220uC.
Uptake of exogenous material by schistosomula in vitro
Schistosomula were co-incubated in 1 ml Complete Medium
169 with either 30 mg Cy5-labeled SmCB1- or mCherry- dsRNA,
200 mg recombinant mCherry protein or 2 mL washed and packed
human erythrocytes. Uptake was monitored as a function of time,
usually every half hour out to 4 h, at 20 h and thereafter, every
day out to 4 days. For Cy5-labeled dsRNA, worms were washed 4
times in Incomplete Medium 169 before imaging with a laser
scanning microscope (LSM 510 META; Carl Zeiss MicroImaging,
Inc.). For mCherry protein, fluorescence was visualized without
washing using an Axiovert 40CFL inverted microscope. Bright
field images of parasites in the presence of erythrocytes were
acquired using an Axiovert 40C inverted microscope.
Results
Of seven defined culture media tested, Basch Medium
169 optimally maintains schistosomula
Prior to RNAi experiments with newly transformed schisto-
somula, we wished to evaluate the effects of different defined
culture media (containing 100 U/ml penicillin and 100 mg/ml
RNAi in S. mansoni Schistosomula
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These effects were visually determined as phenotypic alterations
in parasite motility, shape and translucence [76]. Time-lapse
image recordings, taken at day 7 of the incubation, are provided
as Videos S1, S2, S3, S4, S5, S6, S7 and provide the best visual
medium to compare and contrast the worm responses to the
incubation conditions. Still images from these experiments are
also presented in Figure 1. By the seventh day of incubation,
relative to Basch medium 169, DMEM (high glucose), F-12,
Liebowitz and M199 media had generated varying degrees of
deformed, rounded and/or darkened parasites, often accompa-
nied by slowed and less dynamic motility. In RPMI and
Schneider’s media, additional and more severe effects (degen-
erating parasites and widespread death) were noted, which
appeared as early as day 2 of the incubation and progressed to
approximately .80% parasite mortality by day 7. For RPMI,
this was also case when the medium was exchanged every 2
days. In contrast, in Basch medium 169, parasites were more
uniform in translucency, shape and motility with less than 10%
mortality at day 7. Based on these results, therefore, we
employed Basch medium 169 for all further experiments.
The issue of carry-over contaminating DNA in accurately
measuring RNAi
In spite of the mandatory DNase treatment used to remove PCR-
derived DNA from dsRNA preparations, the possibility existed that
residual DNA would nevertheless serve as template for qPCR
should the qPCR primers be designed to amplify within the
sequence used to synthesize dsRNA [55,74]. This would result in an
apparent lack of, or less efficient, transcript knockdown. That this is
a legitimate concern (and even with best practice to purify dsRNA
according to the appropriate protocol) is shown in Figure S1 using
‘purified’ dsRNA to the tegument-associated SmCB2 transcript as
an example. A concentration-dependent amplification resulted
(Figure S1A) when qPCR primers (Primer set B) were positioned
within the sequence employed as template for reverse transcription
(Figure S1B). In contrast, primer set A, that targeted an area 59 of
the dsRNA template sequence, produced no such amplification.
Direct toxicity of dsRNA to schistosomula, and dose- and
time-dependency of RNAi
Direct toxicity to schistosomula by dsRNA was evident as
greater proportions of parasites that displayed abnormal pheno-
Figure 1. Manifestation of phenotypes in newly transformed S. mansoni schistosomula by various defined culture media. Over the
course of one week’s incubation, parasites in Basch Medium 169 [78] appear robust and uniform in shape and appearance. In contrast, DMEM (high
glucose), F-12, Liebowitz and M199 media generated different degrees of distorted parasites including rounding and darkening that was often
accompanied by slowed and less dynamic motility. For RPMI and Schneider’s medium, parasite rounding, degeneration and death were noted by day
2 of the incubation with .80% parasite mortality by day 7. Images were captured using a Zeiss Axiovert 40 C inverted microscope (106objective)
and a Zeiss AxioCam MRc digital camera controlled by AxioVision 40 version 4.5.0.0 software. These images are best viewed in conjunction with
Videos S1 through S7 (taken at the same magnification) to include the effects of media on parasite motility. A second experiment with the same
media yielded similar results. Scale bars represent 100 mm.
doi:10.1371/journal.pntd.0000850.g001
RNAi in S. mansoni Schistosomula
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outright death, or a combination thereof (Figure 2). Using dsRNA
to mCherry (or CB1, not shown) and at the highest concentration
tested of 210 mg/ml, more than 35% of the parasites appeared
abnormal by days 3 and 6 of the incubation (Figure 2A). At a
concentration of 150 mg/ml, a marked increase in the percentage
of distressed parasites was measured between days 3 (12%) and 6
(35%; Figure 2A and 2B, lower panel). Concentrations below this
(30 and 90 mg/ml) did not increase the percentage of abnormal
parasites above the 12% background for the duration of the
experiment. Thus, we interpret the data to suggest that the upper
concentration limit for dsRNA, without incurring obvious parasite
distress, is approximately 90 mg/ml. Operationally, we chose
30 mg/ml dsRNA to provide an increased margin of safety and
based on the dsRNA dose-dependency tests for CB1 (Figure 3A),
MetAP, NEC and PP2a (not shown) indicating that 30 mg/ml was
sufficient for maximal RNAi. We chose a period of 6 days for co-
incubating dsRNA and parasites as it was sufficient to register
maximal transcriptional suppression of CB1, MetAP and PP2a
(Figure 3B, C and D, respectively).
RNAi, including more than one transcript target, is
selective, however, its efficiency is gene-dependent
Transcripts for the gut-associated proteins CB1, CC and CD
are sensitive to RNAi and are robustly suppressed by .75%
(Figure 4A, B and C, respectively). Importantly, the effect is
selective for the intended mRNA within the pool of gut transcripts
examined. Attachment of the fluorescent Cy5 label to CB1-
(Figure 4A) or CC-(not shown) specific dsRNA does not interfere
with suppression, or the degree of suppression, of the cognate
mRNA. With non-labeled dsRNA targeting CB1, CC and CD,
the RNAi effect was long-term, remaining constant out to 3 weeks
of incubation without exchanging either culture medium or
dsRNA (not shown). For CB1, long-term suppression (.30 days of
incubation) of transcript has been previously noted for schisto-
somula exposed at 3 h [53] and 7 days post-transformation [96].
As exemplified by CB1 and CD (Figure 5A and B, respectively),
RNAi of more than one transcript at the same time is possible in
schistosomula (30 mg/ml dsRNA per transcript target), in this case
with .75% suppression. As found for RNAi of single transcripts,
the effect is again selective within the pool of transcripts examined.
For these experiments, the transcript for cystatin (Cys), a cysteine
protease inhibitor (AY334553.1) [97], was included as a non-
targeted transcript control.
Confirmation of RNAi at the protein level was sought for CC
(Figure 6). A 6-day co-incubation of schistosomula and dsRNA
targeting CC realized a knockdown of the translation product,
measured either as an 80% decrease in the peptidolytic cleavage of
the cathepsin C-selective substrate, GR-AMC (Figure 6A) or as a
loss of the proteolytic signal (at approximately 24 kDa) using the
specific active site-directed probe, bodipy-labeled FY01
(Figure 6B). Activity in the presence of GR-AMC was not
inhibited by the general cysteine protease inhibitor, K11777, or by
CA-074 and Z-Phe-Phe-DMK that target cathepsins B and L,
respectively. This indicates that only cathepsin C activity was
being measured. For CB1, a similar absence of protein was
recorded after dsRNA application using immunoblotting with
monospecific antibodies (not shown).
Robust and selective single and double knockdowns (.75%)
were also possible for the tegument transcript targets CB2,
Figure 2. Direct toxicity by dsRNA to newly transformed schistosomula. Parasites were incubated in a total volume of 1 ml Basch Complete
Medium with various concentrations of dsRNA (aliquots of 70 ml water) to Discosoma sp. mCherry [84]. At days 3 and 6, three photographic fields of
view per dsRNA concentration were taken and those parasites displaying an obvious loss of shape and morphological integrity counted. The data
shown in (A) are the averages of those counts expressed as a percentage of the total number of worms. SD values were less than 10% of the mean.
(B) Images of parasites exposed to different concentrations of dsRNA by day 6 of the incubation: arrowheads indicate examples of distressed worms
induced by 150 mg/ml dsRNA. Data are representative of two experiments. Similar results were observed with dsRNA to SmCB1. Scale bars represent
100 mm.
doi:10.1371/journal.pntd.0000850.g002
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(Figure 7A, B and C, respectively). This was the case within the
pool of tegument transcripts examined and as compared to the
gut-associated CB1 employed as a ‘tissue control’.
For the 5 remaining genes that are considered to be more
generally distributed (MetAP, nMT, PP2a, GSK3, and NEC),
selective single and double (for MetAP, nMT and PP2a)
knockdowns were generated with 30 mg/ml dsRNA per transcript
(Figure 8). However, compared to the gut and tegument targets,
the efficiency of knockdown was more variable. Thus, a decrease
of approximately 75% was recorded for MetAP (Figure 8A);
whereas for nMT and PP2a, decreases of between 40 and 60%
were obtained (Figure 8B and C). GSK3 and NEC transcripts
were more resistant to RNAi with maximum decreases of
approximately 40% (Figure 8D and E). RNAi of each target did
not affect levels of CB1 transcript used as a ‘tissue control’.
Figure 3. Dose and time dependency of RNAi in newly transformed schistosomula. Parasites were incubated with (A) varying
concentrations of dsRNA or (B, C and D) 30 mg/ml dsRNA for various periods up to 6 days. RNAi was measured by qRT-PCR and data expressed
relative to those following parasite exposure to schistosome-unspecific mCherry dsRNA. Asterisks in (A) indicate direct dsRNA toxicity to the parasites
(see text and Figure 2 for details). Each sample was tested in duplicate and representative data from two experiments are shown.
doi:10.1371/journal.pntd.0000850.g003
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gene targets (Figure 8F). Doubling or tripling the concentration to
90 mg/ml dsRNA did not improve RNAi (not shown), nor was it
the case that transcript suppression was greater earlier in the 6-day
incubation period (as shown when processing samples for
transcript levels of MetAP and PP2a at days 2 and 4 of the
incubation; Figure 3C). Thus, in the present experimental system,
the RNAi recorded seems to be the maximal achievable.
No striking or obvious phenotypes were observed upon RNAi of
any of the 11 gene transcripts over the 6-day incubation period.
For the 3 gut-associated and 5 in silico-predicted essential genes,
this was also the case after 3 week co-incubations and whether or
Figure 4. RNAi of gut-associated gene transcripts in newly transformed schistosomula is robust and selective. Parasites were
incubated for 6 days with 30 mg/ml of each of the indicated dsRNA preparations. RNAi was measured by qRT-PCR and data expressed relative to
those following parasite exposure to schistosome-unspecific mCherry dsRNA. A negative control (2ve) in which parasites had not been exposed to
dsRNA was also included. For each of the targeted genes, (A) SmCB1, (B) SmCC and (C) SmCD, the RNAi effect was selective among the pool of gut-
associated transcripts examined. Selective RNAi of SmCB1 was also achieved with 30 mg/ml Cy5-linked dsRNA. Each sample was tested in duplicate
and representative data from two experiments are shown.
doi:10.1371/journal.pntd.0000850.g004
Figure 5. RNAi of more than one gut-associated gene transcript is robust and selective. Newly transformed schistosomula were incubated
for 6 days with either 30 or 60 mg/ml of the indicated dsRNA preparations depending on whether single or double transcript suppression of SmCB1
(A) or SmCD (B) was being attempted. RNAi was measured by qRT-PCR and data expressed relative to those following parasite exposure to
schistosome-unspecific mCherry dsRNA at 60 mg/ml. Included as controls were parasites that had not been exposed to dsRNA (2ve) or that had been
co-incubated with dsRNA to the cysteine protease inhibitor cystatin (Cys). Each sample was tested in duplicate and representative data from two
experiments are shown.
doi:10.1371/journal.pntd.0000850.g005
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shown). For CB1 and CD, the same was also true in the presence
of washed erythrocytes and was independent of whether single or
double RNAi was employed (not shown).
The contribution by electroporation to RNAi is minor and
may depend on the tissue localization of the target
Electroporation has been employed as part of a protocol to
deliver nucleic acids to both adult schistosomes and schistosomula
e.g., [53,57,96,98]. Our experience with electroporation has
entailed some risk of contamination of parasite culture consequent
on the extra handling required to perform this technique. These
issues are of logistical importance when streamlining larger scale
RNAi experiments. We, therefore, devised a series of experimental
conditions for selected gene targets to determine the contribution
to RNAi by electroporation as compared to simple co-incubation.
Co-incubation of dsRNA with schistosomula or electroporation
in the presence or absence of dsRNA followed by co-incubation of
dsRNA with parasites led to robust transcript suppression (.75%)
for each the tissue-representative targets examined, namely CB1
(gut), CB2 (tegument) and MetAP (otherwise; Figure 9). In
contrast, when worms that had been electroporated in the
presence of dsRNA were then immediately washed 10 times prior
to incubation in the absence of dsRNA, the RNAi effect was more
limited. Thus, for the gut proteases CB1 (Figure 9A), CC and CD
(not shown), transcript levels were decreased by between 0 and
15% relative to mCherry. Similarly, only an approximate 20%
decrease in message was recorded for MetAP when the
contribution of electroporation to RNAi was isolated (Figure 9C).
However, for the tegument targets, CB2 (Figure 9B), annexin and
Sm29 (not shown), electroporation alone generated a more
apparent RNAi of approximately 50%. This suggests that
tegument targets may be more amenable to electroporation,
perhaps facilitated by their greater proximity to the transducing
electrical field generated by electroporation. Yet, overall, the
contribution of electroporation, when isolated from the other
experimental parameters, to the RNAi effect is relatively minor,
and consequently could be omitted as an operational parameter
when streamlining larger-scale screens with dsRNA. We note,
however, that what may apply for optimal delivery of long dsRNA
may not be the case for siRNA.
The gut as a mediator of RNAi in newly transformed
schistosomula
Given the above data suggesting that simple co-incubation of
newly transformed parasites and dsRNA is sufficient to mediate
RNAi, we then asked the question whether the gut serves as a
route of entry for dsRNA into the schistosome. The question is
Figure 6. RNAi of SmCC is accompanied by decreased translation product measured as proteolytic activity. (A) Activity in extracts of
schistosomula that had been co-incubated for 6 days with 30 mg/ml mCherry (Ch) or SmCC (CC) dsRNA was measured with the cathepsin C-selective
peptidyl substrate, GR-AMC. Worm extracts were normalized to 0.4 mg of protein per reaction and the proteolytic activity in extracts from parasites
exposed to mCherry dsRNA was set to 100%. (B) Reactivity with the fluorescent cathepsin C-selective activity-based probe (bodipy-labeled FY01; [91])
as assessed by SDS-PAGE. Worm extracts were normalized to 2 mg per labeling reaction. The fluorescent signal at 24 kDa is lost subsequent to
exposure to CC-specific dsRNA. Data in (A) are the average of triplicate values (SD values were less the 5% of the mean). Representative data from two
experiments are shown.
doi:10.1371/journal.pntd.0000850.g006
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parasite mouth is not open until about day 7 of the incubation (i.e.,
indicative of a non-functioning gut) and, therefore, cannot
facilitate RNAi in younger schistosomula [96]. Using Cy5-labeled
dsRNA to CB1, CC or mCherry, we demonstrate that the gut of
schistosomula takes up and concentrates exogenous material
within minutes of their mechanical preparation (Figure 10; results
with CB1 dsRNA shown). Accumulation of the dye was evident
along the gut and in the two terminal cecal chambers by 90 min
post-transformation (Figure 10A). At the same time-point, a
fluorescent signal from accumulated mCherry protein could be
detected (Figure 10B). For both probes, the signal remained visible
during the incubation period of 6 days illuminating the gut ceca as
they elongated posteriorly over time. Consistent with this rapid
onset of gut activity, we could already measure RNAi of CB1 at
between 2 and 4 h post-incubation with dsRNA, an effect that
increased as a function of time (Figure 3B). Finally, we could detect
hemoglobin-derived pigment in the gut of 2 day-old schistosomula
co-incubated with erythrocytes (Figure 10C). Taken together, the
results suggest that the schistosomulum gut is functionally active
within minutes of their preparation from cercariae and seems a
likely route through which RNAi is mediated.
Discussion
Large-scale RNA-dependent gene silencing is an informative
reverse genetic platform to interrogate decreased or loss of gene
function at the protein, pathway, cell and organism levels. RNAi
can also aid the identification of drug targets for the treatment of a
variety of disease states [99,100,101], including those caused by
pathogens [102,103]. For schistosomes, a number of key
components (comprehensive genome and transcriptome data,
interrogable databases, and both in silico and experimental
evidence of the RNAi phenomenon) are now in place to facilitate
the implementation of larger scale RNAi-based screening
campaigns.
In advance, we investigated the sensitivity and selectivity of
RNAi for a set of 11 genes, which contained representatives from
different tissue types – gut, tegument and otherwise. We employed
long (approximately 500 bp) dsRNA rather than siRNA as the
Figure 7. RNAi of one, or more than one, tegument-associated gene transcript is robust and selective. Newly transformed
schistosomula were incubated for 6 days with either 30 or 60 mg/ml of the indicated dsRNA depending on whether single or double transcript
suppression was being attempted. RNAi was measured by qRT-PCR and data expressed relative to those following parasite exposure to schistosome-
unspecific mCherry dsRNA at 60 mg/ml. For each of the targeted genes, (A) SmCB2, (B) SmAx (annexin) and (C) Sm29, the RNAi effect was selective
among the pool of tegument transcripts examined and also with respect to the transcript for the gut-associated protease, SmCB1, used as a ‘tissue
control’. Each sample was tested in duplicate and representative data from two experiments are shown.
doi:10.1371/journal.pntd.0000850.g007
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experiments and based on the assumption that the variety of
siRNAs generated from the parent dsRNA would provide for as
much silencing potential as possible. We focused on mechanically
transformed schistosomula that are both relevant to parasitism in
humans and, compared to adult parasites, available in greater
numbers for automated high throughput screening [76]. In
addition, issues of operational efficiency and simplicity were also
considered, including, choice of culture medium, transfection
strategy, dsRNA time- and dose-dependency and dosing limits. It
was during these studies that the gut was identified as a likely route
for entry of dsRNA into the newly transformed parasite.
The question of which culture medium to use for optimal
maintenance of schistosomula has not been directly evaluated
since the pioneering culture work of Cheever and Weller, and
Clegg in the 1950s and 60s [104,105], and Basch in the early
1980’s [78]. The issue is also relevant to chemical drug discovery
programs that involve co-incubation of schistosomula with
compounds and the recording of phenotypes [76]. Of the seven
media tested here (Basch Medium 169, DMEM, F-12, Liebowitz’s,
M199, RPMI 1640 and Schneider’s), all except Basch Medium
169 induced abnormal phenotypes amounting to darkened and/or
distorted parasites often accompanied by slowed and less dynamic
motility. In the case of Schneider’s and RPMI 1640 media,
widespread death occurred. Of note was the poor survival of
schistosomula in RPMI 1640, a medium that has been previously
employed for a number of RNAi studies with schistosomula
[52,65,96,98]. Our concern was that the high background
mortality observed here would make determinations of an RNAi
effect, either at the mRNA level or, certainly, at the phenotypic
level, difficult. Yet, despite the poor survival in RPMI, RNAi of
CB1 transcript could be decreased to levels similar to those
achieved in Basch Medium 169 (data not shown) - a finding
consistent with the effect observed previously. Nevertheless, based
on the present media tests, we employ Basch Medium 169 as the
medium of choice for maintenance of S. mansoni schistosomula as
mortality remained at approximately 10% out to 4 weeks of
incubation. Indeed, consistent with the earlier report [78], we have
been able to maintain parasites long enough (about 8 months) in
Basch Complete Medium 169 to the point of pairing of males and
females (unpublished data).
Key concerns in any large scale screening campaign are the
occurrence and extent of off-targeting. The possibility of such
phenomena operating in schistosomes has been raised in a recent
report involving RNAi of 32 genes expressed in S. mansoni mother
sporocysts [74,75]. For the smaller set of 11 genes studied here in
schistosomula, we did not observe off-targeting which is encour-
aging for larger scale studies. RNAi, including suppression of more
Figure 8. For 5 other gene transcripts, RNAi of one, or more than one target is selective, but efficiency varies. Newly transformed
schistosomula were incubated for 6 days with either 30 or 60 mg/ml of the indicated dsRNA depending on whether single or double transcript
suppression was being attempted. RNAi was measured by qRT-PCR and data expressed relative to those following parasite exposure to schistosome-
unspecific mCherry dsRNA at 60 mg/ml. For each of the targeted genes, (A) SmMetAP, (B) SmnMT (C) SmPP2a, (D) SmGSK3 and (E) SmNEC, the RNAi
effect was selective among the pool of genes examined and also with respect to the transcript for the gut-associated protease, SmCB1, used as a
‘tissue control’. Likewise, the corollary experiment (F) indicates that RNAi of CB1 does not affect transcript levels of the other gene targets. Each
sample was tested in duplicate and representative data from two experiments are shown.
doi:10.1371/journal.pntd.0000850.g008
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and between the different pools of gut, tegument and generally
distributed transcripts investigated. The finding is also important
as it expands upon previous data for smaller numbers (1 to 3) of
genes of interest [55,65] that demonstrated RNAi specificity
relative to schistosome-unspecific dsRNA preparations used as
Figure 9. Electroporation is not necessary for maximal RNAi in newly transformed schistosomula. Parasites were exposed to 30 mg/ml
dsRNA for representative gut (SmCB1), tegument (SmCB2) and otherwise (SmMetAP) targets and then incubated for 6 days. Experimental parameters
were as follows: E+S, electroporation with dsRNA followed by soaking (i.e., co-incubation with dsRNA); E+W, electroporation with dsRNA then
washing worms 10 times to remove extraneous dsRNA and followed by soaking; E/S, electroporation without dsRNA and then soaking in the
presence of dsRNA; S, soaking with dsRNA without prior electroporation. RNAi was measured by qRT-PCR and data expressed relative to those
following parasite exposure to schistosome-unspecific mCherry dsRNA. Simple soaking of dsRNA targeting either SmCB1 (A) or SmMetAP (C) was
sufficient to achieve maximal RNAi; electroporation had a minor effect. In contrast, for the tegumental protease, SmCB2, (B) (also for SmAx and Sm29,
not shown), electroporation mediated a greater effect, but still not as pronounced as that produced by simple co-incubation. In both (B) and (C),
levels of SmCB1 transcript, employed as a ‘tissue control’, were unaffected. Each sample was tested in duplicate and representative data from two
experiments are shown.
doi:10.1371/journal.pntd.0000850.g009
Figure 10. The gut of newly transformed schistosomula is active and likely facilitates RNAi. After their preparation from cercariae,
schistosomula were incubated with (A) 30 mg/ml Cy5-linked dsRNA targeting SmCB1, (B) 200 mg/ml recombinant mCherry protein or (C) 5 ml washed
and packed human erythrocytes. For each image, the anterior end of the parasite is leftmost and times stated are post-preparation from cercariae.
Both the Cy5-linked dsRNA and mCherry emit a strong fluorescent signal that quickly accumulates in the gut including in the two terminal cecal
chambers. The arrow and arrowheads indicate the acetabular ‘gland ducts’ and acetabular ‘glands’, both being distinct from the developing gut. In
(C), brown material, derived from the digestion of hemoglobin, highlights the parasite gut. Images were captured using: (A) a Zeiss LSM 510 META
confocal microscope and a 633 nm laser for excitation; (B) a Zeiss Axiovert 40 CFL inverted microscope using the Filter Set 20 (ex-546; em-575-640)
and connected to a Zeiss AxioCam HRc digital camera and (C) a Zeiss Axiovert 40 C inverted microscope connected to a Zeiss AxioCam MRc. Both
AxioCAms were operated by AxioVision 40, version 4.5.0.0, software. Scale bars represent 20 mm.
doi:10.1371/journal.pntd.0000850.g010
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schistosomula is consistent with data from similarly designed
experiments for a pool of gut-associated proteases in 3-week old S.
mansoni [54]. That the contemporaneous and selective suppression
of more than one gene is possible in schistosomula could prove
useful in interrogating functional redundancy within protein
systems. An example of such is the network of gut proteases that
digest host proteins [54,79]. Multiple RNAi of component
proteases may help reveal the extent of redundancy and highlight
cooperative relationships in how host proteins are processed.
For both the gut and tegument genes studied, knockdown
efficiency, including after double-targeting, was at least 75%. For
the gut proteases, CC and CB1, transcript knockdown was
mirrored by a substantial decrease or loss of translation product as
determined biochemically with a specific substrate and active site-
directed probe for CC, and a monospecific anti-serum to CB1.
The robust suppression of CB1 and CD recorded here is consistent
with previous studies using schistosomula [53,55,96] and 3 week-
old sub-adult worms [54]. Though our observations did not
include measurements of worm size to statistically discriminate
dsRNA-induced phenotypic alterations [53,55], we noted no
striking abnormalities in parasites co-incubated for 3 weeks with
dsRNA to CB1 and/or CD in the presence or absence of
erythrocytes. This included a previous observation of red-colored,
rather than the normally black, gut contents in a population of
schistosomula exposed to CD-dsRNA in the presence of
erythrocytes– a finding that prompted the suggestion that
diminished CD activity was responsible for the phenotype [55].
At this time, we cannot explain the difference in phenotypic
outcomes, however, we observe that the color of gut contents of
individual schistosomula normally varies from black to brown to
red when cultured in the presence of erythrocytes.
The robust RNAi of gut and tegument targets contrasts with the
more variable efficiencies recorded for the 5 gene targets
considered to be more generally distributed in the parasite and
that had been predicted in silico to be essential [46]. Thus, the
efficiency of RNAi ranged from approximately 75% (MetAP) to
approximately 40% for GSK3 and NEC. We speculate that the
localization of gene expression is in part responsible for this
variation whereby genes expressed in the gut and tegument are
more likely to be efficiently suppressed given their proximity to the
external environment containing dsRNA.
Such gene-to-gene variability in sensitivity to RNAi is likely
inherent when, under a standardized set of conditions such as
those under investigation here, not all gene transcripts will respond
to the same degree. Variable gene responses to RNAi have also
been recently described for S. mansoni mother sporocysts [74,75]
and schistosomula [65] exposed to dsRNA. Transcripts not
decreased below certain critical thresholds will contribute to the
lack of obvious phenotypes arising. This could also explain why
targeting the 5 genes that had been predicted in silico as being
essential to S. mansoni [46] produced no gross phenotypic
alterations, even at near toxic dsRNA concentrations or over an
extended 3-week co-incubation period. Of course, this is aside
from the more direct possibility that the genes are not, after all,
essential to survival of the parasite or the particular developmental
stage in question. In addition, and as discussed previously [51],
even for genes that are sensitive to RNAi, issues such as
developmental plasticity of the schistosome and functional
redundancy in protein function, pathways or networks will limit
the number of readily observable phenotypes. Yet, given these
considerations, literature reports of striking phenotypes post-RNAi
in schistosomula (e.g., [59,63]) would encourage continued loss-of-
function investigations, especially in view of the imperative to
identify new drug targets.
The finding that co-incubation of newly transformed parasites
and dsRNA, without the need for electroporation (i.e., trans-
tegumental delivery of dsRNA), is sufficient to induce robust RNAi
focused our attention on the parasite gut in dsRNA uptake. By
90 min post-production from cercariae we could observe a
concentration of fluorescent macromolecules above background
in the gut that was indicative of rapid and active ingestion of
exogenous material by the parasite. This gut activity during
transformation from the cercarial state is consistent with electron
microscopy studies demonstrating rearrangements of the esopha-
geal environment [106] and earlier observations that transforming
parasites engulf culture fluid [107]. In parallel with the ingestion of
fluorescent materials, we could measure decreased CB1 transcript
2 to 4 hours after co-incubation of worms with specific dsRNA
suggesting that dsRNA, upon ingestion, is both rapidly absorbed
and processed to initiate mRNA suppression. It is possible that the
tegument or other organ systems such as the acetabular glands
[96] or nephridiopore [108] also act as entry points for dsRNA in
nascent schistosomula, however, the present results suggest that
the gut should also be considered as a key contributor. Finally, the
observation of blood products in 2 day-old schistosomula
reinforces the evidence that the gut is quickly put to work by the
parasite in the acquisition of nutrients.
The data reported herein that newly transformed schistosomula
are amenable to RNAi is promising in view of previous reports
observing less efficient or inconsistent suppression (of CB1) in
parasites ,7days old [53,96]. The underlying reasons for these
apparent differences in RNAi kinetics are unclear and could be
reviewed as part of a broader discussion on assay development and
refinement. From the perspective of screen design, however, it is
logistically much simpler to move directly from ‘snails to screens’
employing newly transformed schistosomula without factoring for
both the extra time and handling required for older parasites,
particularly as they seem to be more susceptible to handling
damage than newly transformed schistosomula (unpublished data).
Supporting Information
Figure S1 The influence of qPCR primer positioning on the
amplification of residual PCR product carried over from dsRNA
synthesis. There is no amplification of residual PCR product
(Panel A) when primer pairs (Primer set A) are positioned
upstream from that part of the open reading frame of SmCB2
used to synthesize dsRNA (Panel B). In contrast, Primer set B
(positioned within the sequence used to generate dsRNA) amplifies
residual PCR product in a concentration-dependent manner that
would negatively impact the apparent efficiency of RNAi as
measured by qRT-PCR. Each sample was tested in duplicate and
representative data from two experiments are shown.
Found at: doi:10.1371/journal.pntd.0000850.s001 (0.35 MB TIF)
Table S1 List of primer sequences employed for dsRNA
synthesis (the T7 DNA polymerase binding motif is shown in
bold characters) and quantitative real-time (qRT)-PCR.
Found at: doi:10.1371/journal.pntd.0000850.s002 (0.03 MB XLS)
Video S1 Phenotypic responses of S. mansoni schistosomula upon
incubation in Basch Medium 169. Parasites were maintained for 7
days in medium containing 5% FBS, and 100 U/ml penicillin and
100 mg/ml streptomycin. Time-lapse recordings were captured
with a Zeiss Axiovert 40 C inverted microscope (106magnifica-
tion) connected to a Zeiss AxioCam MRc digital camera that was
under the control of AxioVision 40 version 4.5.0.0 software. Note
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cy, shape and motion with the least background mortality.
Found at: doi:10.1371/journal.pntd.0000850.s003 (3.66 MB
MOV)
Video S2 Phenotypic responses of S. mansoni schistosomula upon
incubation in DMEM (high glucose) medium. Parasites were
maintained for 7 days in medium containing 5% FBS, and 100 U/
ml penicillin and 100 mg/ml streptomycin. Time-lapse recordings
were captured with a Zeiss Axiovert 40 C inverted microscope
(106 magnification) connected to a Zeiss AxioCam MRc digital
camera that was under the control of AxioVision 40 version
4.5.0.0 software.
Found at: doi:10.1371/journal.pntd.0000850.s004 (3.53 MB
MOV)
Video S3 Phenotypic responses of S. mansoni schistosomula upon
incubation in F-12 medium. Parasites were maintained for 7 days
in medium containing 5% FBS, and 100 U/ml penicillin and
100 mg/ml streptomycin. Time-lapse recordings were captured
with a Zeiss Axiovert 40 C inverted microscope (106magnifica-
tion) connected to a Zeiss AxioCam MRc digital camera that was
under the control of AxioVision 40 version 4.5.0.0 software.
Found at: doi:10.1371/journal.pntd.0000850.s005 (3.47 MB
MOV)
Video S4 Phenotypic responses of S. mansoni schistosomula upon
incubation in Liebowitz’s medium. Parasites were maintained for
7 days in medium containing 5% FBS, and 100 U/ml penicillin
and 100 mg/ml streptomycin. Time-lapse recordings were cap-
tured with a Zeiss Axiovert 40 C inverted microscope (106
magnification) connected to a Zeiss AxioCam MRc digital camera
that was under the control of AxioVision 40 version 4.5.0.0
software.
Found at: doi:10.1371/journal.pntd.0000850.s006 (3.44 MB
MOV)
Video S5 Phenotypic responses of S. mansoni schistosomula upon
incubation in M199 medium with Earle’s Salts. Parasites were
maintained for 7 days in medium containing 5% FBS, and 100 U/
ml penicillin and 100 mg/ml streptomycin. Time-lapse recordings
were captured with a Zeiss Axiovert 40 C inverted microscope
(106 magnification) connected to a Zeiss AxioCam MRc digital
camera that was under the control of AxioVision 40 version
4.5.0.0 software.
Found at: doi:10.1371/journal.pntd.0000850.s007 (4.30 MB
MOV)
Video S6 Phenotypic responses of S. mansoni schistosomula upon
incubation in RPMI 1640 medium. Parasites were maintained for
7 days in medium containing 10 mM HEPES, 2 mM glutamine,
5% FBS, and 100 U/ml penicillin and 100 mg/ml streptomycin.
Time-lapse recordings were captured with a Zeiss Axiovert 40 C
inverted microscope (106 magnification) connected to a Zeiss
AxioCam MRc digital camera that was under the control of
AxioVision 40 version 4.5.0.0 software.
Found at: doi:10.1371/journal.pntd.0000850.s008 (2.81 MB
MOV)
Video S7 Phenotypic responses of S. mansoni schistosomula upon
incubation in Schneider’s medium. Parasites were maintained for
7 days in medium containing 5% FBS, and 100 U/ml penicillin
and 100 mg/ml streptomycin. Time-lapse recordings were cap-
tured with a Zeiss Axiovert 40 C inverted microscope (106
magnification) connected to a Zeiss AxioCam MRc digital camera
that was under the control of AxioVision 40 version 4.5.0.0
software.
Found at: doi:10.1371/journal.pntd.0000850.s009 (2.63 MB
MOV)
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